BDRX:US
$1.299
-2.338%
Biodexa Pharmaceuticals plcInsider Activity
Last updated: May 7, 2025, 12:27 PM ET
Profile
Company Description
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications.